

David A Bond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7550882/publications.pdf>

Version: 2024-02-01

46
papers

698
citations

567144

15
h-index

610775

24
g-index

47
all docs

47
docs citations

47
times ranked

1073
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1750-1753. | 0.6 | 1 |
| 2 | CAR T-cell therapy for B-cell lymphoma. <i>Current Problems in Cancer</i> , 2022, 46, 100826. | 1.0 | 26 |
| 3 | Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 342.e1-342.e5. | 0.6 | 5 |
| 4 | Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442. | 0.2 | 6 |
| 5 | Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386. | 0.6 | 59 |
| 6 | Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942. | 1.7 | 21 |
| 7 | Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683. | 3.3 | 45 |
| 8 | Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. <i>Journal of Clinical Medicine</i> , 2021, 10, 1207. | 1.0 | 11 |
| 9 | Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659. | 2.5 | 28 |
| 10 | Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310. | 1.1 | 3 |
| 11 | The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2372-2382. | 0.6 | 35 |
| 12 | HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862. | 2.5 | 24 |
| 13 | Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189. | 2.5 | 21 |
| 14 | Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel. <i>Blood</i> , 2021, 138, 1756-1756. | 0.6 | 6 |
| 15 | Feasibility of High-dose Methotrexate Administered on Day 1 of (R)CHOP in aggressive non-Hodgkin Lymphomas. <i>Blood Advances</i> , 2021, , . | 2.5 | 7 |
| 16 | Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib. <i>Blood</i> , 2021, 138, 3731-3731. | 0.6 | 3 |
| 17 | Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. <i>Blood</i> , 2021, 138, 3851-3851. | 0.6 | 1 |
| 18 | Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study. <i>Blood</i> , 2021, 138, 1425-1425. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303. | 2.0 | 18 |
| 20 | Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. <i>Blood Advances</i> , 2020, 4, 4648-4652. | 2.5 | 53 |
| 21 | Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 903-921. | 0.9 | 17 |
| 22 | Second cancer incidence in CLL patients receiving BTK inhibitors. <i>Leukemia</i> , 2020, 34, 3197-3205. | 3.3 | 45 |
| 23 | <p>Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6573-6581. | 1.0 | 10 |
| 24 | Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262. | 2.5 | 29 |
| 25 | Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3. | 0.6 | 1 |
| 26 | Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020, 136, 24-26. | 0.6 | 0 |
| 27 | Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50. | 0.6 | 1 |
| 28 | EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020, 136, 4-6. | 0.6 | 0 |
| 29 | A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 29-29. | 0.6 | 2 |
| 30 | Targeting BTK in CLL: Beyond Ibrutinib. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 197-205. | 1.2 | 98 |
| 31 | Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019, 37, 471-480. | 0.8 | 74 |
| 32 | The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397. | 0.6 | 3 |
| 33 | Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402. | 0.6 | 9 |
| 34 | Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775. | 0.6 | 5 |
| 35 | Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753. | 0.6 | 9 |
| 36 | Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483. | 0.6 | 1 |
| 38 | Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525. | 0.6 | 10 |
| 39 | A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4091-4091. | 0.6 | 3 |
| 40 | The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891. | 0.6 | 0 |
| 41 | Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4571-4571. | 0.6 | 1 |
| 42 | North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553. | 0.6 | 0 |
| 43 | Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018, 132, 451-451. | 0.6 | 3 |
| 44 | Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018, 132, 453-453. | 0.6 | 1 |
| 45 | Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153. | 0.6 | 0 |
| 46 | Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597. | 0.6 | 2 |